ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,765 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBaselFoRx Therapeutics AG
FoRx Therapeutics AG Logo
Verified· 4 sourcesTrust Score
Summary

About the company

The core activity of FoRx Therapeutics AG is the development of active ingredients for cancer treatment, in particular the development of first-in-class compounds for the treatment of cancer, with a focus on inhibiting targets involved in the repair of collapsed DNA replication forks.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.0/5

FoRx Therapeutics AG

✓ Offered5
Development of cancer drugs
Preclinical and clinical development of precise therapeutics for therapy-resistant cancers, focusing on DNA replication stress and DNA damage response pathways.
PARG inhibitor FORX-428
Lead program for a potent and selective PARG inhibitor in Phase 1 clinical development for the treatment of therapy-resistant cancers.
Research on DNA replication stress
Research into the biological role of DNA replication stress and the targeted modulation of DNA repair pathways in cancer cells.
Pipeline development of additional drug programs
Development of additional programs in lead optimization and lead identification, including FORX-002 and FORX-003 for DNA damage response and replication stress.
Investor Relations
Investor information, company overview, financing and development updates, and contacts for institutional, corporate and strategic investors.
Trust & reputation

ranQ Trust Score of FoRx Therapeutics AG: 4.0 out of 5.0

Trust Score4.0/ 5.0

High

x

Data basis 100% · As of October 2026

FoRx Therapeutics AG scores 62.3 out of 100 points in the Reputation area of the ranQ Trust Score. This area carries 42% of the weighting.
x
CriterionValueWeight
  • Review quality: The average rating across all connected sources, smoothed against the industry mean. So 5.0 stars from three reviews do not outrank 4.7 from three hundred.65.024%
  • Review volume: The number of reviews across all sources. The scale is logarithmic: the first reviews count the most, and the maximum is reached at 50 reviews.49.510%
  • Review recency: The age of the most recent review. Two-year-old reviews deliberately sit in the middle, because that is normal for Swiss SMEs. Only after three years without a new voice does the value drop markedly.70.08%
FoRx Therapeutics AG scores 81.6 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.75.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.82.07%
FoRx Therapeutics AG scores 86.7 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).86.722%
FoRx Therapeutics AG scores 27.2 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.34.34%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.20.04%
Qualifications+0.00

FoRx Therapeutics AG reaches a ranQ Trust Score of 4.0 out of 5.0 — rated «High». The rating draws, among other things, on 4.3 out of 5 stars from 6 customer reviews. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Reviews

Aggregated rating

Aggregated rating
4.3
of 5

Aggregated from 6 reviews across all connected sources

Sources
GGoogle4.36
★TrustpilotSoon
PProvenExpertSoon

Further sources are added continuously and factored into the ranQ Rating.

Press

Media

December 18, 2025Media
FoRx Therapeutics raises $50 million to advance clinical trials
startupticker.ch

Knowledge

No knowledge articles yet

Once FoRx Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

FoRx Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank FoRx Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of FoRx Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Lichtstr. 35
4056 Basel
Opening hours
Mon
09:00 - 17:00
Tue
09:00 - 17:00
Wed
09:00 - 17:00
Thu
09:00 - 17:00
Fri
09:00 - 17:00
Sat
Closed
Sun
Closed

At a glance

Legal form
Corporation
UID
CHE-336.934.781
Founded
2019 · 7 years
Last commercial register change
September 29, 2026
Employees
21 to 50
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    RG
    RXcel GmbH
    Basel
    LM
    Laevoroc Medical AG
    Basel
    RS
    Regeneron Switzerland GmbH
    Basel
    SC
    St. Clara Forschung AG
    Basel
    VA
    VectivBio AG
    Basel
    IM
    Inari Medical Europe GmbH
    Basel
    BA
    BioVersys AG
    Basel
    CT
    CORETAG Therapeutics AG
    Basel